Transcripts Ribomic Inc.

Stocks

Market Closed - Japan Exchange 02:30:00 2026-08-21 EDT			5-day change	1st Jan Change
81.00 ^JPY	-2.41%		+2.53%	+3.85%

08-13	Ribomic Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
07-02	Ribomic Enrolls First Patient in Phase III Trials of Umedaptanib Pegol for Achondroplasia Treatment	MT

22-11-11	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023	CI
22-08-09	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023	CI
22-05-13	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Full Year Ending March 31, 2022	CI
21-11-09	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2022	CI
21-08-06	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2022	CI
21-05-25	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2022	CI
21-02-11	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2021	CI
20-08-06	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Full Year Ending March 31, 2021	CI
20-05-13	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Full Year Ending March 31, 2021	CI
20-02-06	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2020	CI
19-11-27	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2020	CI
19-08-23	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2020	CI
17-08-21	Ribomic Inc. Announces Non-Consolidated Earnings Results for the First Quarter Ended June 30, 2017; Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2018	CI